Proliferative retinopathies: Animal models and therapeutic opportunities

Current Neurovascular Research

Volumn 12, Issue 2, 2015, Pages 189-198

  Villacampa, Pilar ^a,b   Haurigot, Virginia ^a,b   Bosch, Fatima ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

AAV vectors; Gliosis; IGF I; Neovascularization; Neurodegeneration; PEDF; Retinopathy; VEGF

Indexed keywords

NEUROPROTECTIVE AGENT; PIGMENT EPITHELIUM DERIVED FACTOR; SOMATOMEDIN C; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BLINDNESS; CONTROLLED STUDY; DIABETIC RETINOPATHY; GLIA; GLIOSIS; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA; RETINA NEOVASCULARIZATION; SAFETY; ANIMAL; DISEASE MODEL; HUMAN;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; RETINAL NEOVASCULARIZATION;

EID: 84930854655     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202612666150311113535     Document Type: Article

References (112)

1. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552-63.
2. Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye (London, England). 2002; 16: 242-60.
3. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122: 477-85.
4. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 global update of available data on visual impairment: A compilation of populationbased prevalence studies. Ophthalmic Epidemiol 2004; 11:67-115.
5. Ferris FL, 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2.
6. Foster A, Resnikoff S. The impact of Vision 2020 on global blindness. Eye (London, England). 2005;19:1133-5.
7. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981; 88: 583-600.
8. Gottfredsdottir MS, Stefansson E, Jonasson F, Gislason I. Retinal vasoconstriction after laser treatment for diabetic macular edema. Am J Ophthalmol 1993; 115:64-7.
9. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. The New England J Med 1994; 331:1480-7.
10. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006; 141: 456-62.
11. Lightman S, Towler HM. Diabetic retinopathy. Clinical Corner-Stone. 2003; 5:12-21.
12. Triantafylla M, Massa HF, Dardabounis D, et al. Ranibizumab for the treatment of degenerative ocular conditions. Clin Ophthalmol (Auckland, NZ). 2014; 8: 1187-98.
13. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology. 2012; 119: 1388-98.
14. Ford JA, Elders A, Shyangdan D, Royle P, Waugh N. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: An indirect comparison in a systematic review. BMJ (Clinical research ed). 2012; 345:e5182.
15. Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: The 24-Week Results of the VIBRANT Study. Ophthalmology. 2014.
16. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247-54.
17. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-48.
18. Folk JC, Stone EM. Ranibizumab therapy for neovascular agerelated macular degeneration. The New England journal of medicine. 2010;363:1648-55.
19. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48.
20. Schwartz SG, Flynn HW, Scott IU. Endophthalmitis after intravitreal injections. Exp Opinion Pharmacotherapy 2009; 10: 2119-26.
21. Redmond TM, Yu S, Lee E, et al. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nature Genetics. 1998; 20: 344-51.
22. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. The New England journal of medicine. 2008; 358: 2231-9.
23. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Jr., Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. The New England J Med 2008; 358: 2240-8.
24. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Human Gene Therapy. 2008; 19: 979-90.
25. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 2009; 374: 1597-605.
26. Pang JJ, Chang B, Hawes NL, Hurd RE, Davisson MT, Li J, et al. Retinal degeneration 12 (rd12): A new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA). Mol Vision 2005; 11:152-62.
27. Veske A, Nilsson SE, Narfstrom K, Gal A. Retinal dystrophy of Swedish briard/briard-beagle dogs is due to a 4-bp deletion in RPE65. Genomics 1999; 57: 57-61.
28. Islam MS. Animal models of diabetic neuropathy: progress since 1960s. J Diabetes Res 2013; 2013: 149452.
29. Kong LL, Wu H, Cui WP, et al. Advances in murine models of diabetic nephropathy. J Diabetes Res 2013; 2013: 797548.
30. Sima AA, Chakrabarti S, Garcia-Salinas R, Basu PK. The BB-rat-an authentic model of human diabetic retinopathy. CurrEye Res 1985; 4(10): 1087-92.
31. Midena E, Segato T, Radin S, et al. Studies on the retina of the diabetic db/db mouse. I. Endothelial cell-pericyte ratio. Ophthalmic Res. 1989; 21(2): 106-11.
32. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005; 46(6): 2210-8.
33. Danis RP, Yang Y. Microvascular retinopathy in the Zucker diabetic fatty rat. Invest Ophthalmol Vis Sci . 1993; 34(7): 2367-71.
34. Feit-Leichman RA, Kinouchi R, Takeda M, Fan Z, Mohr S, Kern TS, et al. Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes. Invest Ophthalmol Vis Sci 2005; 46(11): 4281-7.
35. Yamada H, Yamada E, Higuchi A, Matsumura M. Retinal neovascularisation without ischaemia in the spontaneously diabetic Torii rat. Diabetologia. 2005;48(8):1663-8.
36. Obrosova IG, Drel VR, Kumagai AK, Szabo C, Pacher P, Stevens MJ. Early diabetes-induced biochemical changes in the retina: comparison of rat and mouse models. Diabetologia. 2006;49:2525-33.
37. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008; 118: 526-33.
38. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996; 114: 1219-28.
39. Hellstrom A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013; 382:1445-57.
40. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci . 1994; 35(1): 101-11.
41. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci 1993; 34(3): 576-85.
42. Saito Y, Park L, Skolik SA, Alfaro DV, Chaudhry NA, Barnstable CJ, et al. Experimental preretinal neovascularization by laserinduced venous thrombosis in rats. Curr Eye Res 1997; 16(1):26-33.
43. Yoshioka M, Kayo T, Ikeda T, Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 1997; 46(5): 887-94.
44. van Eeden PE, Tee LB, Lukehurst S, Lai CM, Rakoczy EP, Beazley LD, et al. Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularization. Invest OphthalmolVisSci. 2006;47(10):4638-45.
45. Rakoczy EP, Ali Rahman IS, Binz N, Li CR, Vagaja NN, de PM, et al. Characterization of a mouse model of hyperglycemia and retinal neovascularization. Am J Pathol 2010; 177(5): 2659-70.
46. Clements RS, Jr., Robison WG, Jr., Cohen MP. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. JDiabetes Complications. 1998; 12(1): 28-33.
47. Cheung AK, Fung MK, Lo AC, et al. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes. 2005; 54(11): 3119-25.
48. Bogdanov P, Corraliza L, J AV, et al. The db/db mouse: A useful model for the study of diabetic retinal neurodegeneration. PloS one. 2014; 9: e97302.
49. Carmo A, Cunha-Vaz JG, Carvalho AP, Lopes MC. Nitric oxide synthase activity in retinas from non-insulin-dependent diabetic Goto-Kakizaki rats: correlation with blood-retinal barrier permeability. Nitric Oxide 2000; 4(6): 590-6.
50. Agardh CD, Agardh E, Zhang H, Ostenson CG. Altered endothelial/pericyte ratio in Goto-Kakizaki rat retina. J Diabetes Complications 1997; 11(3):158-62.
51. Lu ZY, Bhutto IA, Amemiya T. Retinal changes in Otsuka longevans Tokushima Fatty rats (spontaneously diabetic rat)-possibility of a new experimental model for diabetic retinopathy. Jpn J Ophthalmol 2003; 47(1): 28-35.
52. Yang JH, Kwak HW, Kim TG, Han J, Moon SW, Yu SY. Retinal Neurodegeneration in Type II Diabetic Otsuka Long-Evans Tokushima Fatty Rats. Invest Ophthalmol Vis Sci 2013; 54(6): 3844-51.
53. Kakehashi A, Saito Y, Mori K, et al. Characteristics of diabetic retinopathy in SDT rats. Diabetes Metab Res Rev 2006; 22(6): 455-61.
54. Shinohara MMTAKA. The Spontaneously Diabetic Torii (SDT) rat with retinopathy lesions resembling those of humans. In: E.Shafrir, editor.: Boca Raton, Fla, USA: CRC Press; 2007. p. 311-21.
55. Sasase T. Pathophysiological characteristics of diabetic ocular complications in spontaneously diabetic torii rat. J Ophthalmol 2010; 2010: 615641.
56. Kern TS, Barber AJ. Retinal ganglion cells in diabetes. JPhysiol. 2008;586(Pt 18):4401-8.
57. Kern TS, Miller CM, Tang J, Du Y, Ball SL, Berti-Matera L. Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop. Mol Vis 2010; 16: 1629-39.
58. Mowat FM, Gonzalez F, Luhmann UF, Lange CA, Duran Y, Smith AJ, et al. Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy. Am J Pathol 2012; 180: 1726-39.
59. Zhang Y, Fortune B, Atchaneeyasakul LO, McFarland T, Mose K, Wallace P, et al. Natural history and histology in a rat model of laser-induced photothrombotic retinal vein occlusion. Curr Eye Res 2008; 33: 365-76.
60. George M, Ayuso E, Casellas A, Costa C, Devedjian JC, Bosch F. Beta cell expression of IGF-I leads to recovery from type 1 diabetes. J Clin Invest 2002; 109(9): 1153-63.
61. Budd GC, Pansky B, Glatzer L. Preproinsulin mRNA in the rat eye. Invest Ophthalmol Visual Sci 1993; 34: 463-9.
62. Haurigot V, Villacampa P, Ribera A, Llombart C, Bosch A, Nacher V, et al. Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown. J Biol Chem 2009; 284(34): 22961-9.
63. Ruberte J, Ayuso E, Navarro M, et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest 2004; 113(8): 1149-57.
64. Haurigot V, Villacampa P, Ribera A, et al. Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy. PLoSOne. 2012; 7(7): e41511.
65. Villacampa P, Ribera A, Motas S, et al. Insulin-like Growth Factor I (IGF-I)-induced chronic gliosis and retinal stress lead to neurodegeneration in a mouse model of retinopathy. J Biol Chem 2013.
66. Grant M, Russell B, Fitzgerald C, Merimee TJ. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes. 1986; 35(4): 416-20.
67. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N Engl J Med 1983; 309(9): 527-30.
68. Inokuchi N, Ikeda T, Imamura Y, Sotozono C, Kinoshita S, Uchihori Y, et al. Vitreous levels of insulin-like growth factor-I in patients with proliferative diabetic retinopathy. Curr Eye Res 2001; 23(5): 368-71.
69. Kondo T, Vicent D, Suzuma K, Yanagisawa M, King GL, Holzenberger M, et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 2003;111(12):1835-42.
70. Agardh EACD. Diabetic Retinopathy. In: R.A.DeFronzo HFHKaPZ, editor.: John Wiley & Sons; 2004. p. 1187-206.
71. Adamis AP. Is diabetic retinopathy an inflammatory disease? BrJOphthalmol. 2002; 86(4): 363-5.
72. Ferrara N. Vascular endothelial growth factor. Arteriosclerosis, Thromb Vasc Biol 2009; 29: 789-91.
73. Winkler JL, Kedees MH, Guz Y, Teitelman G. Inhibition of connective tissue growth factor by small interfering ribonucleic acid prevents increase in extracellular matrix molecules in a rodent model of diabetic retinopathy. Mol Vision 2012; 18: 874-86.
74. Van Geest RJ, Leeuwis JW, Dendooven A, et al. Connective tissue growth factor is involved in structural retinal vascular changes in long-term experimental diabetes. J Histochem Cytochem: Official J Histochem Soc 2013; 62: 109-18.
75. Hellstrom A, Carlsson B, Niklasson A, et al. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metabol 2002; 87: 3413-6.
76. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5: 1390-5.
77. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Seminars Cancer Biol 1996; 7: 147-54.
78. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, et al. The angiofibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PloS one 2008; 3: e2675.
79. Heng LZC, O.; Peto, T.; Tadros, C.; Ng, E.; Sivaprasad, S.; Hykin, P.G. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabet Med. 2012;30:640-50.
80. Mizutani M, Gerhardinger C, Lorenzi M. Muller cell changes in human diabetic retinopathy. Diabetes. 1998;47(3):445-9.
81. Curtis TM, Hamilton R, Yong PH, McVicar CM, Berner A, Pringle R, et al. Muller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products. Diabetologia 2011; 54(3): 690-8.
82. Zong H, Ward M, Madden A, et al. Hyperglycaemia-induced proinflammatory responses by retinal Muller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia. 2010; 53(12): 2656-66.
83. Bianchi R, Giambanco I, Donato R. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol Aging 2010; 31(4): 665-77.
84. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414(6865): 813-20.
85. Zong H, Ward M, Stitt AW. AGEs, RAGE, and diabetic retinopathy. CurrDiabRep. 2011;11(4):244-52.
86. Fischer AJ, Scott MA, Zelinka C, Sherwood P. A novel type of glial cell in the retina is stimulated by insulin-like growth factor 1 and may exacerbate damage to neurons and Muller glia. Glia. 2010; 58(6): 633-49.
87. Gerhardinger C, Costa MB, Coulombe MC, Toth I, Hoehn T, Grosu P. Expression of acute-phase response proteins in retinal Muller cells in diabetes. Invest Ophthalmol Vis Sci 2005; 46(1): 349-57.
88. de Kozak Y, Cotinet A, Goureau O, Hicks D, Thillaye-Goldenberg B. Tumor necrosis factor and nitric oxide production by resident retinal glial cells from rats presenting hereditary retinal degeneration. Ocul Immunol Inflamm 1997; 5(2): 85-94.
89. Nakazawa T, Hisatomi T, Nakazawa C, et al. Monocyte chemoattractant protein 1 mediates retinal detachment-induced photoreceptor apoptosis. Proc Natl AcadSci USA. 2007; 104(7): 2425-30.
90. Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW. When NRF2 talks, who's listening? AntioxidRedoxSignal. 2010; 13(11):1649-63.
91. Zhong Q, Mishra M, Kowluru RA. Transcription factor Nrf2-mediated antioxidant defense system in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2013; 54(6): 3941-8.
92. Vardatsikos G, Sahu A, Srivastava AK. The insulin-like growth factor family: molecular mechanisms, redox regulation, and clinical implications. Antioxid Redox Signal 2009; 11(5): 1165-90.
93. Williams CR, Lu X, Sutliff RL, Hart CM. Rosiglitazone attenuates NF-kappaB-mediated Nox4 upregulation in hyperglycemiaactivated endothelial cells. Am J Physiol Cell Physiol 2012; 303(2): C213-C23.
94. Shirao Y, Kawasaki K. Electrical responses from diabetic retina. Prog Retin Eye Res 1998; 17(1): 59-76.
95. Holopigian K, Greenstein VC, Seiple W, Hood DC, Carr RE. Evidence for photoreceptor changes in patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38(11): 2355-65.
96. Tyrberg M, Lindblad U, Melander A, Lovestam-Adrian M, Ponjavic V, Andreasson S. Electrophysiological studies in newly onset type 2 diabetes without visible vascular retinopathy. Doc Ophthalmol 2011; 123(3):193-8.
97. Fulton AB, Hansen RM, Moskowitz A, Akula JD. The neurovascular retina in retinopathy of prematurity. Progress in retinal and eye research. 2009; 28: 452-82.
98. Noma H, Funatsu H, Mimura T. Association of electroretinographic parameters and inflammatory factors in branch retinal vein occlusion with macular oedema. Br J Ophthalmol 2012; 96: 1489-93.
99. Civil A, van Genesen ST, Klok EJ, Lubsen NH. Insulin and IGF-I affect the protein composition of the lens fibre cell with possible consequences for cataract. Exp Eye Res 2000; 70: 785-94.
100. Rand L, Cavallerano, J., and Aiello, L. P. Nonretinal Ocular Complications of Diabetes Mellitus. In: DeFronzo R, Ferrannini, E., Keen, H., Zimmet, P. , editor. International Textbook of Diabetes Mellitus: John Wiley & Sons; 2004. p. 1207-18.
101. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science (New York, NY). 1999; 285: 245-8.
102. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8: 349-57.
103. Mori K, Gehlbach P, Yamamoto S, et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Investigative ophthalmology & visual science. 2002; 43: 1994-2000.
104. Raisler BJ, Berns KI, Grant MB, Beliaev D, Hauswirth WW. Adeno-associated virus type-2 expression of pigmented epitheliumderived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci USA 2002;99:8909-14.
105. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Human Gene Therapy 2006; 17: 167-76.
106. Barnstable CJ, Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Progress Retinal Eye Res 2004; 23: 561-77.
107. Bennett J, Wilson J, Sun D, Forbes B, Maguire A. Adenovirus vector-mediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Visual Sci 1994; 35: 2535-42.
108. Hellstrom M, Ruitenberg MJ, Pollett MA, et al. Cellular tropism and transduction properties of seven adeno-associated viral vector serotypes in adult retina after intravitreal injection. Gene Therapy 2008; 16: 521-32.
109. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genetics 2011; 12: 341-55.
110. Zhu XB, Y.; Yu, W.; Pan, C.; Jin, E.; Song, D.; Xu, Q.; Yao, Y.; Huang, L.; Tao, Y.; Li, X.; Zhao, M. The effects of pleiotrophin in proliferative diabetic retinopathy. PloS one. 10. United States 2015. p. e0115523.
111. Ng T, Fortino V, Pelaez D, HS C. Progress of mesenchymal stem cell therapy for neural and retinal diseases. World J Stem Cells 2014; 6: 111-9.
112. Roozafzoon R, Lashay A, Vasei M, et al. Dental pulp stem cells differentiation into retinal ganglion-like cells in a three dimensional network. Biochem Biophys Res Commun. 2014; 457: 154-60.